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Abstract
Congenital myasthenic syndromes (CMS) are a group of rare, inherited disorders characterized by compromised function of the
neuromuscular junction, manifesting with fatigable muscle weakness. Mutations in MYO9A were previously identified as
causative for CMS but the precise pathomechanism remained to be characterized. On the basis of the role of MYO9A as an actin-
based molecular motor and as a negative regulator of RhoA, we hypothesized that loss of MYO9A may affect the neuronal cyto-
skeleton, leading to impaired intracellular transport. To investigate this, we used MYO9A-depleted NSC-34 cells (mouse motor
neuron-derived cells), revealing altered expression of a number of cytoskeletal proteins important for neuron structure and in-
tracellular transport. On the basis of these findings, the effect on protein transport was determined using a vesicular recycling
assay which revealed impaired recycling of a neuronal growth factor receptor. In addition, an unbiased approach utilizing prote-
omic profiling of the secretome revealed a key role for defective intracellular transport affecting proper protein secretion in the
pathophysiology of MYO9A-related CMS. This also led to the identification of agrin as being affected by the defective transport.
Zebrafish with reduced MYO9A orthologue expression were treated with an artificial agrin compound, ameliorating defects in
neurite extension and improving motility. In summary, loss of MYO9A affects the neuronal cytoskeleton and leads to impaired
transport of proteins, including agrin, which may provide a new and unexpected treatment option.
Introduction
The neuromuscular junction (NMJ) is a tightly controlled func-
tional unit, with highly specialized pre- and post-synaptic re-
gions that must function in a coordinated manner for effective
NMJ transmission to be achieved. The complex organization of
the neuronal cytoskeleton is crucial for both NMJ formation and
functionality. Actin in particular is a highly important compo-
nent of the cytoskeleton as it enables complex and dynamic
movement of cargo for junctional signalling and formation by
using members of the myosin superfamily. Rho-GTPases and
Rho-GEFs (GDP/GTP nucleotide exchange factors) are critical in
the control of actin dynamics and disturbed Rho has already
been implicated in the vulnerability of the peripheral nervous
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system (1,2). Other cytoskeletal components, also important for
NMJ functionality, include microtubules which facilitate the
long-distance transport necessary for motor neurons and neu-
rofilaments that provide pre-dominantly structural support to
neurons but are implicated in a range of peripheral neuropa-
thies (3–5).
Various mutations in critical NMJ proteins are known to
cause primary defects in neuromuscular transmission and lead
to the clinical picture of congenital myasthenic syndromes
(CMS). The main symptom of patients with CMS is fatigable
muscle weakness that usually starts in childhood and can dis-
rupt the skeletal, respiratory, bulbar and ocular muscles de-
pending on the protein involved. CMS constitute a group of
genetically heterogenic disorders and causative genes can be
broadly categorized as pre-synaptic, synaptic or post-synaptic.
Recently, we expanded the catalogue of known pre-synaptic
CMS causative genes by describing recessive missense muta-
tions in the unconventional myosin encoding gene, MYO9A,
present in three patients showing a severe neonatal phenotype
with both respiratory and bulbar involvement (6).
Unconventional myosins are actin based molecular motors
that are present in almost all eukaryotic cells. There are two
class 9 myosin proteins expressed in humans; MYO9A and
MYO9B. MYO9A follows the same basic structural composition
as other unconventional myosins, containing a force generat-
ing myosin motor domain in the head region which binds ac-
tin, as well as an extended tail region that contains a Rho-GAP
(Rho GTPase-activating protein) domain. The presence of this
Rho-GAP domain, unique to class 9 myosins, infers the ability
to negatively regulate the activity of Rho by converting it from
its active GTP-bound state to an inactive GDP-bound state,
with the pathway summarized in Supplementary Material,
Figure S1A (7). Because of direct interaction with actin and in-
fluence of actin via the Rho-GAP domain, MYO9A has been im-
plicated in the regulation of filamentous-actin (f-actin)
dynamics, a process that is crucial for the structure of the pre-
synaptic nerve terminal, vesicular trafficking and neurotrans-
mitter release, as highlighted in Supplementary Material,
Figure S1B (8–11).
Following preliminary investigations, we were already able
to demonstrate an in vitro role for MYO9A in neurite branching
and extension utilizing the mouse motor neuron-like hybrid
cell-line (NSC-34). Depletion of the MYO9A orthologues from
zebrafish, myo9aa and myo9ab, also supported a role for this
unconventional myosin in formation of the NMJ and in move-
ment of the developing zebrafish. Neurons are extremely vul-
nerable to transport deficiencies and thus any defects here
may clearly affect the finely balanced organization of the NMJ.
Defects in plectin, a cross-linking protein for intermediate fila-
ments, have already been associated with CMS (12). However,
the precise molecular mechanisms in CMS caused by per-
turbed cytoskeleton still remain elusive. Therefore, in this
study we aim to systematically widen the pathological impli-
cations of cytoskeletal involvement in CMS. On the basis of
our previous results and other identified cytoskeletal and exo-
cytotic functions of MYO9A, here our hypothesis was that
MYO9A disrupts NMJ function in CMS by affecting the neuro-
nal cytoskeleton, thus impacting on vesicular trafficking and
protein secretion. To address this hypothesis, we have em-
ployed both biased and unbiased approaches: immunological
based assays to assess structural integrity and vesicular traf-
ficking proficiency of NSC-34 cells depleted for MYO9A and un-
biased proteomic profiling of the secretome of control and
MYO9A-depleted NSC-34 cells.
Results
MYO9A-depletion affects the cytoskeleton of NSC-34
cells
In order to observe the cytoskeleton in MYO9A-depleted NSC-34
cells, immunofluorescent staining and immunoblot analysis of
F-actin, b-tubulin, periaxin and neurofilament was performed.
This revealed an increase in fluorescence intensity of f-actin in
the MYO9A-depleted NSC-34 cells (Mann–Whitney test,
P¼ 0.0016, n> 34, Fig. 1A and B), confirmed by western blot as
shown in Figure 1C. There is also an increase in the number of
cells displaying actin stress fibre-like structures in MYO9A-
depleted cells as compared with controls, from 5% to 85% re-
spectively (n> 65, Supplementary Material, Fig. S2A). This is fur-
ther supported by orientation analysis of actin positive fibres,
revealing a significant decrease in the dispersion (an increase in
organization) of fibre direction in MYO9A-depleted cells (Mann–
Whitney test, P< 0.0001, n> 65, Supplementary Material, Fig.
S2B). Neurofilament, periaxin and b-tubulin, important struc-
tural components of neuronal cells, all had decreased fluores-
cence intensity (Mann–Whitney test, P< 0.0001, n> 28) in cells
depleted for MYO9A (Fig. 1A and B), with b-tubulin and neurofi-
lament (light chain) also confirmed via western blot (Fig. 1C).
As MYO9A has been shown to act as an inhibitor of RhoA ac-
tivity, cells were also treated with a compound to inhibit the
downstream function of the RhoA pathway (ROCK inhibitor, Y-
27632). The contribution of the RhoA pathway to the cytoskeletal
defects observed could then be determined (RhoA pathway out-
lined in Supplementary Material, Fig. S1A). Actin levels were in-
creased in control cells following application of Y-27632, and
decreased in MYO9A-depleted cells to a level similar to untreated
controls, as shown in Figure 1A, B and C (Mann–Whitney test,
P¼ 0.484, n> 25). b-Tubulin also returned to a level not signifi-
cantly different to that of treated control cells (Mann–Whitney
test, P¼ 0.126, n> 26), however, this remained significantly less
than the untreated controls (Mann–Whitney test, P< 0.0001,
Fig. 1A, B and C). Y-27632 also increased the level of periaxin fluo-
rescence in the MYO9A-depleted cells to a level comparable to
untreated controls (Mann–Whitney test, P¼ 0.912, n> 30, Fig. 1A
and B). Inhibition of the RhoA pathway was unable to rescue the
decrease in neurofilament, furthering the significant decrease in
levels as compared with untreated controls (Mann–Whitney test,
P< 0.0001, n> 87, Fig. 1A, B and C). Therefore, a proportion of the
effect of MYO9A-depletion on the cellular cytoskeleton can be at-
tributed to interaction with the RhoA pathway. Treatment with
Y-27632 also induced neurite extension in both control and
MYO9A-depleted NSC-34 cells, suggesting that the already de-
scribed neurite extension in NSC-34 cells depleted for MYO9A re-
sults from perturbed RhoA signalling.
As described above, we discovered a dysregulation of actin in
MYO9A-depleted NSC-34 cells. Actin was previously used to con-
firm the depletion of MYO9A (6). Therefore, we performed a qPCR
to confirm MYO9A knockdown using an alternative control gene,
Pgk1, to normalize results between control and MYO9A-depleted
cells. MYO9A-depleted cells display a 4-fold significant reduction
in Myo9a expression as compared with the control NSC-34 ex-
pression levels (unpaired t-test, P¼ 0.0022, Fig. 1D).
Vesicular recycling is impaired in NSC-34 cells depleted
for MYO9A
Lack of MYO9A is hypothesized to impact vesicular recycling
processes, including endosomal recycling in nerve cells, due to
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Figure 1. Effect of MYO9A-depletion on the cytoskeleton. (A) Immunofluorescent staining of control and MYO9A-depleted NSC-34 cells with and without over-night
treatment of Y-27632. Cytoskeletal components b-tubulin, periaxin, neurofilament and actin, were assessed. Longer neurites are observed in treated cells, and MYO9A-
depleted cells display increased stress fibre-like structures as shown in the inset image. Scale bars¼20mm. (B) Graphs showing the corrected total cell fluorescence for
levels of b-tubulin (n>26), periaxin (n>30), neurofilament (n>87) and actin (n> 33) in each cell/treatment condition. Mann–Whitney test, NS¼not significant, *P0.05,
**P 0.01, ***P 0.001, ****P0.0001, MKD¼MYO9A-depleted, error bars¼meanþ standard error of the mean. (C) Immunoblot analysis for actin (42 kDa), b-tubulin
(50 kDa) and neurofilament (light chain—70 kDa) with a Coomassie loading control, in control and MYO9A-depleted cells. MKD¼MYO9A-depleted. (D) Graph demon-
strating the relative expression ratio of Myo9a in control and Myo9a-shRNA transfected NSC-34 cells as obtained from qPCR results, utilizing Pgk1 as a control.
MKD¼MYO9A-depleted, error bar represents meanþ standard error of the mean, unpaired t-test **P<0.01.
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perturbed cytoskeleton. To assess this, a paradigmatic surface
receptor, TrkA, fused with a GFP-tag was transiently transfected
into NSC-34 control and MYO9A-depleted cells. Following appli-
cation of NGF, a proportion of the receptors will be internalized
and their return to the surface can be tracked over-time.
Results obtained from both control and MYO9A-depleted
cells were normalized using pre-NGF values to allow direct com-
parison at each time point. Following NGF application, the NSC-
34 cells demonstrated endocytosis of the TrkA receptors and by
60 min almost all control cells had successfully exocytosed the
receptors to pre-NGF levels, which was complete by 180 min
(Fig. 2A). In the MYO9A-depleted cells, by 60 min significantly
less cells had managed to return receptors to the surface as
compared with control NSC-34 cells (Mann–Whitney test,
P¼ 0.029, n¼ 200). By 180 min 10% fewer cells were expressing
TrkA receptors on the surface than before NGF application, and
this was significantly less than the control NSC-34 cells (Mann–
Whitney test, P¼ 0.028, n¼ 200). Representative images showing
internalized and externalized receptors are shown in Figure 2C.
To determine whether the lack of receptor expression on the
surface of MYO9A-depleted NSC-34 cells at 180 min was due to
more receptors being targeted for degradation rather than recy-
cling, we also performed immunoblots on the cells at time
points 0, 60 and 180 min. This revealed that there was no in-
creased degradation of TrkA receptors in MYO9A-depleted cells
as compared with the controls (Mann–Whitney test, P¼ 0.400)
and thus the lack of exocytosis is most likely based on a defect,
in part, of the recycling pathway (Fig. 2B).
Time-lapse microscopy, in which the TrkA-positive vesicles
were tracked over a period of ten minutes, revealed a significant
decrease in the speed of the receptor trafficking in MYO9A-
depleted cells as shown in Figure 2D (Mann–Whitney test,
P< 0.0001, n¼ 10). An example time-lapse video is shown in
Supplementary Material, Video S1, as well as evidence that
global endocytosis and exocytosis is impaired through the use
of an FM 1–43 dye (Supplementary Material, Fig. S3). Following
on from our results using the ROCK inhibitor to partially rescue
the cytoskeletal defects, we also treated cells with Y-27632 and
performed the time-lapse analysis. A significant increase in
speed of GFP-positive vesicles in MYO9A-depleted cells treated
with Y-27632 was achieved as compared with untreated MYO9A
KD cells, as well as treated control cells (Mann–Whitney test,
P< 0.0001, n¼ 12). Hence, our combined findings clearly suggest
an impaired vesicular transport upon MYO9A-depletion in vitro,
partially due to perturbed cytoskeletal organization as a pre-
requisite of proper transport of proteins packed in vesicles.
Secretomic analysis of NSC-34 cells
Following the observation that intracellular transport is impaired
in cells depleted for MYO9A, a secretome study was performed in
order to determine whether this impairment also affected proper
secretion of proteins from the nerve cells. Proteins secreted from
NSC-34 wild-type and MYO9A-depleted cells were collected and
subjected to label-free shotgun proteomic analysis. This ap-
proach captured the abundance of 1532 proteins and of these we
found there to be 46 proteins with increased and 30 with de-
creased extracellular abundance, highlighting the defect we are
seeing in impaired protein transport and release (Fig. 3A and B,
Supplementary Material, Table S2). Of particular importance is
the identification of a 5.4-fold decrease in secretion of agrin from
the MYO9A-depleted NSC-34 cells, a key mediator in the develop-
ment of the NMJ and a well characterized protein involved in
CMS pathology (13–15). Reduced agrin secretion is highlighted in
Figure 3C, with an absence of ion peaks corresponding to the
LYVGGLPEEQVATVLDR peptide in a 3D montage unique to agrin
as detected in the secretomic analysis. In this context, a signifi-
cant increase in the intracellular immunofluorescent signal for
agrin is also demonstrated in cells lacking MYO9A, in Figure 3D
and E, to further support this finding (Mann–Whitney test,
P< 0.0001, n> 92). Corroborating with our hypothesis that trans-
port/secretory defects can be partly attributed to the dysregula-
tion of the RhoA pathway, application of Y-27632 was able to
significantly reduce the intracellular accumulation of agrin, how-
ever, this was still significantly higher than treated control cells
(Mann–Whitney test, P¼ 0.003). Other interesting proteins identi-
fied in the secretomic analysis include neuronal ubiquitin hydro-
lase (UCHL1), inverted formin 2 (INF2), dihydropyrimidinase-
related protein 5 (DPYL5) and peptidyl-prolyl cis-trans isomerase
FKBP10 (FKBP10).
Analysis of sub-cellular localizations of the proteins identified
with altered abundances has been performed utilizing Uniprot
(http://www.uniprot.org/; date last accessed November 5, 2017),
Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/; date last
accessed November 5, 2017), LOCATE (sub-cellular localization
database: http://locate.imb.uq.edu.au/; date last accessed
November 5, 2017) and MGI (Mouse Genome Informatics: http://
www.informatics.jax.org/; date last accessed November 5, 2017)
and revealed known secretion or extracellular localization of 64
out of the affected 76 proteins (Supplementary Material, Table S2).
The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD007178.
Treatment of zebrafish with agrin compound—NT-1654
Neural agrin, a protein identified with decreased abundance in
secretome data for MYO9A-depleted cells, is an important me-
diator of NMJ development and maintenance and mutations in
AGRN itself can cause CMS (13). Therefore, we hypothesized
that the lack of agrin secretion in MYO9A CMS may be contrib-
uting to the phenotype we observe and thus we tested the effect
of treating the myo9aa/ab MO zebrafish with a novel agrin com-
pound; NT-1654. This compound is composed of a 44 kDa frag-
ment of agrin that is not only soluble but also resistant to
breakdown by neurotrypsin at the NMJ and has already proven
successful in the treatment of various mouse models of disease
(16). Varying concentrations of NT-1654 were trialled, from
0.15 ng to 2.4 ng per injection. A dosage of 0.15 ng was selected
for use as over 50% of the zebrafish survived and we still ob-
served a functional effect. In order to determine the effect of
NT-1654 on NMJ development in zebrafish we injected one-cell
stage embryos with the compound, or with myo9aa/ab MOs
(2 ng/0.2 ng respectively), as described (6) or with both the agrin
compound and the MOs. Various functional and morphological
parameters were then assessed for changes.
Injection of the agrin compound alone lead to 26% more em-
bryos dying by 48 hpf, whereas the MO decreased survival rate
by 5% and both combined by 59% as compared with control
zebrafish (n¼ 100, Fig. 4A). However, as this study has been de-
signed to be a proof of principal, demonstrating the beneficial
effects of agrin restoration in vivo, the dose was not further
optimized.
Spontaneous movement of zebrafish within the chorion,
characterized by repetitive tail movements, begins at 17 hpf,
peaks at 19 hpf and continues to 27 hpf. These movements are
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thought to be indicative of neuronal development and are inde-
pendent of supraspinal input (17,18). Control zebrafish moved
on average 4.5 times in 1 min, while MO injection reduced this
to 3.186 (unpaired t-test, P¼ 0.0009) and a combined treatment
of MO with NT-1654 was able to rescue this to 4.295 (unpaired
t-test versus control P¼ 0.6435, versus MO P¼ 0.0079, n> 40), as
shown in Figure 4B. A representative image of the spontaneous
movements recorded in the fish is depicted in Figure 4C.
CMS patients exhibit varying degrees of muscle weakness
that is fatigue related, and therefore we assessed the ability of
the zebrafish to swim while measuring various outputs. At
27 hpf some zebrafish begin to display signs of swimming be-
haviour, defined as small tail movements that propel the zebra-
fish forward by at least one body length, however, these become
much more pronounced and easy to measure later in develop-
ment around 48 hpf (18). Therefore at 48 hpf we performed a
touch-evoked tactile stimulation response assay, whereby the
zebrafish are touched on the back of the head by a pipette tip
and the response recorded, example shown in Supplementary
Material, Video S2. A characteristic movement is usually per-
formed in which the zebrafish flips backwards and swims away
from the stimuli. Here, we utilized a modified tracking protocol
that employs the use of the TrackMate plugin (ImageJ), to allow
the assessment of swimming speed, initial zebrafish accelera-
tion and also the distance swam after tactile stimulation (aver-
age n¼ 34). Speed of swimming is shown in Figure 4D, and here
the addition of NT-1654 is shown to improve velocity from
19.02 mm/s to 19.27 mm/s, although this was not significant (un-
paired t-test, P¼ 0.9466). Myo9aa/ab MO fish exhibited slow
swimming responses, which was significantly reduced to
6.786 mm/s (unpaired t-test, P< 0.0001). NT-1654 treatment res-
cued this phenotype, improving swimming speed to 15.44 mm/s
which did not show significant differences to the controls (un-
paired t-test, P¼ 0.1675), but was significantly increased as com-
pared with MO-treated larvae (unpaired t-test, P< 0.0001).
Distance travelled is shown in Figure 4E, and this was also
improved by the application of NT-1654, with total displace-
ment increasing between controls and treated fish from
34.58 mm to 45.82 mm respectively, although this increase was
not significant (unpaired t-test, P¼ 0.1341). Myo9aa/ab MO zebra-
fish were not able to swim as far as controls, averaging a dis-
tance of just 15.47 mm (unpaired t-test, P¼ 0.006). However,
combined treatment of MO with NT-1654 increased the swim-
ming distance after stimulation to 24.67 mm, which was a sig-
nificant increase compared with myo9aa/ab MO zebrafish
(unpaired t-test, P¼ 0.0244) and was no longer significantly dif-
ferent to controls (unpaired t-test, P¼ 0.0622).
Finally, initial acceleration was assessed, which is reported
to reach a maximal value within 0.2 s of tactile stimulation and
is proportional to the force generating capacity of the skeletal
muscle and thus is indicative of proper NMJ function (19). As
shown in Figure 4F, acceleration follows a similar pattern to
other movement parameters, with control zebrafish on average
accelerating by 8.13 mm/s2 which is not significantly increased
by NT-1654 treatment alone (9.116 mm/s2, unpaired t-test,
P¼ 0.531). In myo9aa/ab MO fish acceleration is decreased signif-
icantly to 2.865 mm/s2 (unpaired t-test, P< 0.0001), and then in-
creased significantly to 5.918 mm/s2 when NT-1654 is applied
(unpaired t-test, P¼ 0.0007), which is now not significantly dif-
ferent to control zebrafish (unpaired t-test, P¼ 0.428).
Figure 2. Effect of MYO9A on vesicular recycling. (A) Graph depicting the change in TrkA receptor localization over-time in control and MYO9A KD cells following NGF
application to induce internalization (Mann–Whitney test, *P0.05). Values have been normalized to pre-NGF levels to allow direct comparison at each time point and
error bars represent the mean6 standard error of the mean, NGF¼nerve growth factor. (B) Expression of TrkA at time 0, 60 and 180 min, following application of nerve
growth factor. Results shown are relative to control cells at time 0 min. Error bars represent mean6 standard error of the mean. (C) Representative images of internal-
ized and surface TrkA-GFP receptors to show how receptors were classified, scale bars¼20mm. (D) Live-cell time lapse microscopy allowed speed of internalized, GFP
positive TrkA receptors to be quantified over a time period of 10 min for cells untreated or treated with a ROCK inhibitor (Y-27632). Absolute values are shown and error
bars represent meanþ standard error of the mean, Mann–Whitney test ****P0.0001. MKD¼MYO9A-depleted.
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In order to determine whether these functional improve-
ments seen through application of NT-1654 are also reflected at
the level of the NMJ, staining for the pre-synaptic motor neu-
rons and post-synaptic AChRs was performed at 48 hpf (Fig. 4G).
The myo9aa/ab MO zebrafish exhibited truncated motor axons
as described previously (6), and those treated with NT-1654 de-
veloped as normal and were often indistinguishable to controls.
In zebrafish treated with both the MO and NT-1654, even those
with curved tails, demonstrated an improved phenotype. This
included restoration of motor neuron branching and extension,
reaching normal length as in controls. There was also an in-
crease in AChR cluster intensity as shown in Figure 4G, which
could also be observed in wild-type fish treated with NT-1654.
Discussion
Unveiling the pathophysiology of CMS caused by mutations in
the gene encoding unconventional myosin protein, MYO9A, is
an important objective for improving our understanding of how
defects in cytoskeletal motor proteins might lead to NMJ disor-
ders. On the basis of cytoskeletal and vesicular defects seen in
other NMJ/neurodegenerative disorders, including various sub-
types of ALS such as ALS2 and other familial forms, as well as
CMT2E, we hypothesized that loss of MYO9A might cause a sim-
ilar effect in CMS and would lead to a disrupted cytoskeleton in
our in vitro NSC-34 cell model (20–22). There have been previous
reports regarding the effects of MYO9A-depletion on the actin
filament network in other cell types such as bronchial epithelial
cells and kidney tubules, as MYO9A is not only an actin-based
molecular motor but also acts as a Rho GTPase (8,10,23). In order
to obtain deeper insights into the pathomechanism of MYO9A
CMS we therefore performed a combined analysis involving
both unbiased proteomics to identify novel disease substrates
and a range of functional assays.
Prior to testing our hypotheses, the reduction of MYO9A in
our in vitro model was re-confirmed using qPCR, as the previ-
ously published reference gene for normalization (Actin) was
since found to be dysregulated in our cells, and there are no
working commercially available anti-bodies for western blot in
mice. Therefore, we repeated our qPCR with Pgk1 as a reference
gene, an established normalization control for neuronal cells
(24). Immunofluorescent and immunoblotting investigation of
NSC-34 cells lacking MYO9A confirmed the presence of defects
in the cytoskeleton, including an increase in the expression of
actin and a decrease in neurofilament, b-tubulin and periaxin
(which interacts with the dystroglycan complex, thus linking
the basal lamina to cytoskeleton). An increase in actin was ac-
companied by the formation of a considerable actin stress fibre
network. This corroborates with reports that addition of RhoA
to fibroblasts in culture leads to the rapid formation of stress
Figure 3. Secretomic analysis of control and MYO9A-depleted NSC-34 cells. (A) Schematic cell diagram outlining in which cellular compartments the dysregulated pro-
teins are implicated. (B) Volcano plot for secretomic analysis of control NSC-34 cells compared with MYO9A KD cells. (C) 3D montage of agrin peptide peaks
(LYVGGLPEEQVATVLDR) as identified in the secretomic profile in control and MYO9A KD NSC-34 cells. An Absence of agrin can be observed in the MYO9A KD cells. (D)
Immunofluorescent staining of control and MYO9A-depleted NSC-34 cells showing an upregulation of agrin within the cell (corroborating with reduced secretion),
scale bars¼20mm. (E) Graph showing the corrected total cell fluorescence for levels agrin in each cell/treatment condition (n>92). Mann–Whitney test, **P0.01,
****P0.0001, MKD¼MYO9A-depleted, error bars¼meanþ standard error of the mean.
6 | Human Molecular Genetics, 2018, Vol. 00, No. 00
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy054/4866401
by University of Newcastle user
on 08 March 2018
fibres, as we have reduced negative regulation of RhoA with our
MYO9A-depletion (25,26). Treatment of these cells with Y-
27632, a compound that blocks the action of Rho-associated
protein kinase (ROCK, a protein kinase activated by RhoA), was
able to rescue the increase in actin and to reduce it to levels
similar to control cells. This was also coupled with a decrease in
the presence of stress fibres, which is in agreement with the
role of ROCK in promotion of stress fibre formation in cells (27).
With regards to the other cytoskeletal abnormalities observed, a
decrease in neurofilament has also been reported in NSC-34
cells expressing mutant SOD1, as an in vitro model of the neuro-
degenerative disease, ALS. However, whether this decrease
plays an injurious or protective role remains unclear (28).
Treatment of MYO9A-depleted cells with the Y-27632 was un-
able to rescue the loss of neurofilament observed, suggesting
dynamics of neurofilament are not under the control of the
RhoA pathway here. b-Tubulin, a component of the microtubule
network, was also decreased in MYO9A-depleted NSC-34 cells
Figure 4. Effect of NT-1654 treatment in MYO9A-depleted zebrafish. (A) Graph depicting the survival rate of control, NT-1654 injected, MO injected and MOþNT-1654
injected zebrafish at 48 hpf (n¼100). (B) Movements performed by zebrafish within the chorion at 24 hpf in 1 min. Unpaired t-test, NS¼not significant, **P0.01, n>40.
(C) Example of chorion movement showing a full rotation of the zebrafish tail indicated by white arrows. (D) Speed, (E) distance and (F) initial acceleration of zebrafish
swimming away following tactile stimulation at 48 hpf as calculated using TrackMate (ImageJ), n>34. Unpaired t-test, NS¼not significant, *P0.05, **P 0.01,
***P0.001, ****P 0.0001, error bars represent meanþ standard error of the mean. (G) Immunofluorescent staining of 48 hpf zebrafish (control, NT-1654/MO/MOþNT-
1654 injected) to visualize the neuromuscular junctions. SV2 stains pre-synaptic motor neurons and a-bungarotoxin detects the post-synaptic AChRs. MO injected fish
display shortened axons (white arrow) and this is rescued by the application of NT-1654. AChR clusters also appear more prominent following addition of NT-1654
(white arrow head). Scale bars¼50mm. MO¼morpholino, hpf¼hours post-fertilization, AChRs¼acetylcholine receptors, SV2¼ synaptic vesicle protein 2.
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and this was partly rescued by Y-27632 treatment which has
been observed previously in podocyte cells (29). A reduction in
complex microtubule network formation has also been ob-
served in other cell models for motor-neuron related diseases,
including mutant SOD1 NSC-34 cells (30). We similarly assessed
periaxin using immunofluorescence, as it is a structural protein
previously linked to neurodegenerative disorders that affect the
peripheral nervous system (31,32). Treatment with Y-27632 was
also able to increase periaxin to levels not significantly different
from controls, demonstrating that periaxin dynamics are at
least partly regulated by the MYO9A-controlled RhoA pathway
which has not previously been reported. Hence, these combined
findings underline a significant role of MYO9A in cytoskeletal
maintenance via modulation of the ROCK pathway.
As disruption of the cytoskeleton was observed, we next
wanted to address whether vesicular trafficking and recycling of
proteins were functioning appropriately, as both actin and mi-
crotubule networks are important for all aspects of vesicular
transport, from intracellular movement to regulation of endo
and exocytosis (33–35). In order to address this question, we em-
ployed the use of a paradigmatic growth factor receptor, TrkA,
as internalization can be stimulated by applying NGF. However,
the use of TrkA is also relevant as impaired TrkA signalling has
been linked to perturbed neurotransmission paralleled by con-
comitant and progressive loss of selected pre-synaptic and vesi-
cle trafficking proteins, and in relation to CMS, TrkA is also able
to modulate the release of ACh from basal forebrain neurons
(36,37). A similar assay has been performed by Roos et al., utiliz-
ing the epidermal growth factor receptor, and other studies
have performed analysis of TrkA-GFP following nerve growth
factor application and reported similar internalization of recep-
tors and ability to track movements using live-cell confocal mi-
croscopy (38–40). The recycling assay performed here revealed
defective recycling in MYO9A-depleted cells, and this was fur-
ther confirmed by live cell imaging in which slower vesicular
trafficking was observed that could be significantly improved by
the application of Y-27632, therefore linking the morphological
observations of this study with functional changes. There was
also no increase in TrkA receptor degradation in MYO9A-
depleted cells to account for the lack of receptor surface expres-
sion after 3 h. In neurodegenerative diseases such as ALS there
is a measurable decrease in the speed of axonal transport in
motor neurons, as well as loss of motor proteins that occurs as
an early event in the pathophysiology (41), thus defective intra-
cellular dynamics may be a common pathological hallmark.
Furthermore, performing an additional experiment, we were
able to confirm that there is not only a defect in TrkA dynamics
but also a global disruption to endo and exocytosis through
the use of an FM 1–43 dye, suggesting that perturbed protein
transportation represents a down-stream event of MYO9A
pathophysiology.
Prompted by the knowledge that neurotransmitters and
other factors important for NMJ function are transported to the
active zone of nerve terminals by vesicular-mediated transport
before exocytosis into the synaptic cleft, we also hypothesized
that secretion might be affected in MYO9A-depleted cells. To
test this assumption, we performed secretomic analysis to al-
low identification of any mis-secreted proteins. Of the 76 pro-
teins with significantly altered abundances, 64 have been
reported to be secreted or have an extracellular localization.
However, for other proteins found to be increased in the extra-
cellular supernatant of MYO9A-depleted cells, a direct participa-
tion in the underlying pathophysiology can be assumed. One of
those is INF2, a CMT-associated protein which accelerates
polymerization and depolymerization of actin sub-units (42,43).
This known function of INF2 directly links to our pathomorpho-
logical cytoskeletal findings also affecting actin and suggests
that abnormal cytoskeleton upon MYO9A-depletion is caused
by more complex molecular processes affecting a variety of pro-
teins responsible for the build-up and maintenance of the struc-
tural components. This hypothesis is further supported by the
fact that FKBP10 (also increased in the extracellular supernatant
of MYO9A-depleted cells), as a molecular chaperone, can regu-
late muscle actin expression (44). As MYO9A-depleted cells and
zebrafish also exhibit defects in axon extension the presence of
dysregulated proteins involved in axon extension and guidance
are particularly interesting, including DPYL5 that has not previ-
ously been reported to be secreted, but also ANGP1, SRPX2 and
TICN2 (45–48). While other proteins are known to be secreted,
their dysregulation may still be important for MYO9A-related
NMJ defects. For example, the neuronal ubiquitin hydrolase,
UCHL1, is important for the maintenance and structure of the
NMJ and mutations in UCHL1 can cause a motor neuropathy
(49). A knockout UCHL1 mouse exhibits impaired synaptic
transmission at the NMJ, as well as loss and accumulation of
vesicles at the nerve terminal, thus may be important for the
pathology we observe in MYO9A-depleted cells (50).
Furthermore, other proteins may suggest the activation of res-
cue mechanisms, such as the upregulation of pigment
epithelium-derived factor (PEDF), a neurotrophic factor that acts
as a neuroprotective agent in the nervous system. Finally, one
of the most important findings in this secretomic study was the
identification of decreased agrin secretion. Agrin is an impor-
tant mediator of post-synaptic endplate differentiation and
function and is secreted from the nerve terminal in order to ini-
tiate a number of downstream signalling pathways at the NMJ
(14,15). Additionally, mutations in agrin itself can cause CMS,
thus dysfunction in agrin action is already known to be patho-
logical at the NMJ (13).
There are nine reported cases of agrin CMS to date, and only
three for MYO9A, however, some phenotypic overlaps are pre-
sent including the manifestation of both proximal and distal
muscle weakness with respiratory involvement (6,13–15,51).
Defining treatable-units is an important concept in the thera-
peutic intervention of rare diseases (such as CMS with NT-1654
as a promising drug). There are a number of features in MYO9A
patients that do not appear in those with AGRN mutations, such
as hypotonia, delayed motor milestones and ocular/bulbar in-
volvement, therefore indicating that there are other factors in-
volved in MYO9A pathophysiology as discussed above.
Nevertheless, rescuing the agrin downregulation may lead to a
valuable improvement to patient symptoms and has been
shown to have beneficial effects in other disease models such
as a severe SMA mouse in which a reduction in agrin had also
recently been identified (52). A C-terminal, 44 kDa agrin frag-
ment (NT-1654—Neurotune) engineered to be soluble, neuro-
trypsin resistant and still able to cluster AChRs, has been used
with success to treat mice that have undergone disassembly of
the NMJ in sarcopenia or nerve injury (16). Replacement of agrin
through the expression of a motor neuron-specific transgene
has also proven effective in mice with spinal muscular atrophy
by increasing NMJ area and reducing intermediate filament ac-
cumulation (52). The SARCO mouse, a model of sarcopenia, also
undergoes functional muscle strength improvements when
treated with NT-1654 (16). Very recently Li and co-workers
showed that NT-1654 attenuated clinical severity, effectively
promoted the clustering of AChRs at NMJs, and alleviated the
impairment of NMJ transmission, as well as the reduction of
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muscle-specific kinase (MuSK) in a rat model of experimental
autoimmune myasthenia gravis (53). One of the most promising
features of the NT-1654 treatment in particular is that it is exog-
enously applied, thus removing the requirement for complex
gene therapy in patients. It also avoids the problem observed in
the MYO9A-depleted cells of defects in vesicular transport and
secretion, as it is clear that the cells are still synthesizing agrin
due to the large intracellular accumulation of agrin present, but
that it is not secreted by the nerve terminal. Thus, this fragment
can act directly on the post-synaptic muscle fibre without ini-
tially relying on transport machinery in the nerve.
Mouse neural agrin displays a 54% homology with zebrafish,
which increases to 60% when analysing only the Laminin G-like
2, EGF-like 4 and Laminin G-like 3 domains included within the
NT-1654 compound. Replacement of agrin in the myo9aa/ab MO
zebrafish using this mouse-derived fragment was successful in
rescuing the movement defects we observe, as well as NMJ mor-
phology. The improvement at 24 hpf of the chorion movements
due to agrin injection implies it is rescuing the early develop-
ment of the NMJ as expected, and we see further benefits at
48 hpf in speed and distance travelled when the zebrafish are
able to swim away from a tactile stimulus. Acceleration of
zebrafish is a direct measure of the force produced by a muscle
contraction, and this is also improved, providing a functional
measure that nerve to muscle transmission is working appro-
priately (19). Analysis of the NMJs of agrin-injected morphant
fish revealed an improvement in neurite extension, which is im-
paired in fish lacking myo9aa/ab as previously reported (6). This
suggests the addition of agrin is also improving the nerve exten-
sion, and corresponding pre-synaptic improvements are also re-
ported in NT-1654-treated SARCO mice, as well as mice that
have undergone a sciatic nerve crush injury (16). In a number of
fish we also observe an increase in AChR staining, in both agrin
only and agrin/MO zebrafish, which is unsurprising when con-
sidering the role of agrin in clustering of AChRs. While here we
saw a high level of embryo death when co-injecting the MO and
agrin, likely due to the amount of exogenous material being in-
jected, it is important to note that this is just a proof of principal
experiment demonstrating that agrin replacement ameliorates
some of the NMJ phenotype we see in vivo. This supports our in
vitro proteomic and cellular analysis data and provides a start-
ing point for future development of therapeutic strategies that
will be generated.
Conclusions
In this study, our combined functional and biochemical studies
utilizing NSC34-cells as a pre-synaptic in vitro system support
the already speculated role of MYO9A in maintenance of the
neuronal cytoskeleton and moreover demonstrated a detrimen-
tal downstream-effect on vesicular transport and protein secre-
tion. As a result of this, we observe a lack of agrin secretion
which could be rescued with application of an exogenous agrin
fragment in vivo, thus leading to the identification of a protein
of potential therapeutic impact for patients. Discovery of this
underlying pathophysiology links two sub-types of CMS to-
gether (Agrin and MYO9A) with regards to their molecular basis.
This connection highlights the need for in-depth molecular
analysis of genes causing NMJ disorders to find common patho-
mechanisms for which we can invoke similar treatment
strategies.
Materials and Methods
Cell culture
NSC-34 cells stably depleted for MYO9A using shRNA-mediated
knockdown as described previously (6) and control knockdown
cells were cultured to sub-confluence in Dulbecco’s modified
Eagle medium (DMEM; Life Technologies) supplemented with
10% foetal bovine serum, 100 units/ml penicillin/streptomycin
and 3 mg/ml puromycin to maintain selective pressure. To gen-
erate the control knockdown line, NSC-34 cells were transfected
with a control shRNA (Santa Cruz Biotechnology, 108060) using
Lipofectamine 2000 (ThermoFisher Scientific) according to man-
ufacturer’s instructions, as previously described (6).
Quantitative reverse transcriptase PCR
Control and MYO9A-depleted cells (5 106) were trypsinized
and homogenized using a Tissue Ruptor. Cells were transferred
to an RNeasy Mini spin column (RNeasy Mini Kit, Quiagen) and
RNA extracted according the manufacturer’s instructions. RNA
was eluted in RNase-free water and quantified using a nano-
drop. MYO9A depletion was confirmed by quantitative reverse
transcription polymerase chain reaction (qRT-PCR) using
PowerSYBR Green Master Mix according to manufacturer’s in-
structions (Applied Biosystems, 4368706), as b-actin which had
previously been used to normalize the qRT-PCR results has
since been identified as dysregulated in the MYO9A-depleted
cells. Here the qRT-PCR was repeated with another housekeep-
ing gene; PgK1 (50-GGAGCGGGTCGTGATGA-30 and 50-GCCTT
GATCCTTTGGTTGTTTG-30) as has been performed elsewhere
(24). Following confirmation of primer annealing temperature
and reaction efficiency, three biological replicates in triplicate
were run for Myo9a and PgK1, with a corresponding no template
control. The relative expression ratio (RER) was determined us-
ing the formula:
RER of Myo9a ¼ 2
DCttargetðKDcontrolÞ
2DCtref ðKDcontrolÞ
where DCt is the difference in crossing points, ref is the corre-
sponding value for the reference gene and KD refers to the
MYO9A knockdown cells.
Immunofluorescence in cells
NSC-34 cells (control and MYO9A-depleted) were fixed in 1:1 4%
paraformaldehyde: growth medium at 37C for 5 min and
permeabilized in 0.1% TritonTM X-100 in phosphate buffered sa-
line (PBS) for 10 min. Blocking was performed using 4% bovine
serum albumin (BSA) in PBS with 0.1% Tween (PBS-T) at room
temperature for 1 h. Anti-bodies used are shown in
Supplementary Material, Table S1 and were diluted in 1% BSA in
PBS-T, and washes carried out using PBS-T. Samples were
mounted in ProLong Diamond Anti-fade Mountant with DAPI
(Molecular probes). For cells treated with a ROCK inhibitor
(InSolutionTM Y-27632—Calbiochem), the compound was ap-
plied at 3 nM in serum-free growth medium over-night (cells
without Y-27632 were also grown for 24 h in serum-free me-
dium). Staining was then performed as outlined above. Cells
were visualized using a Nikon A1R laser scanning confocal, with
oil-immersion 40 or 60 objectives. In order to quantify the
fluorescence intensity of various anti-bodies applied to NSC-34
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cells, Fiji ImageJ was utilized to obtain average fluorescence, cell
area and integrated density of individual cells at a 40 magnifi-
cation. For each image, three regions without cells were also
measured to establish a mean background fluorescence value.
Corrected total cell fluorescence (CTCF) was then calculated us-
ing the equation below:
CTCF ¼ Integrated density–ðarea of selected cell
x mean fluorescence of background readingsÞ
The presence or absence of stress fibre-like structures was
manually assessed in cells imaged at 60 and 40 objectives. A
directionality plugin on ImageJ was also utilized to determine
the orientation of the actin filament network in the cells (http://
imagej.net/Directionality; date last accessed November 5, 2017).
Immunoblotting
Cells were washed three times in PBS before scraping cells di-
rectly into ice-cold lysis buffer [RIPA buffer with protease inhibi-
tor tablet (Roche)] to generate whole protein extracts. Those were
maintained at 4C with constant agitation for 30 min, centrifuged
for 20 min at 1750g at 4C, then heated to 95C for 5 min in 2
Laemmli buffer (Bio-Rad). Equal loading of samples was con-
firmed by Coomassie staining. Adjusted lysate quantities were
then subjected to SDS-polyacrylamide gel electrophoresis (PAGE)
and proteins transferred to polyvinylidene difluoride-membranes
(Millipore). The membranes were blocked with 5% low-fat dried
milk in Tris-buffered saline (TBS) and 0.1% Tween (TBS-T) for 1 h
at room temperature. Primary anti-bodies were then applied
over-night in blocking milk at 4C, as listed in Supplementary
Material, Table S1. Following TBS-T washes, membranes were in-
cubated with secondary anti-bodies as shown in Supplementary
Material, Table S1, for 1 h at room temperature. Following three
washes in TBS-T and one wash in TBS, bound anti-bodies were
detected using either the Odyssey CLx Imaging System (b-actin
and b-tubulin), or enhanced chemiluminescent substrate
(SuperSignal West Femto; Pierce, Neurofilament).
Vesicular recycling assay
NSC-34 control and MYO9A-depleted cells were cultured to 80%
confluency in six well plates on coverslips and transfected with
2 mg Tropomyosin receptor kinase A (TrkA)-GFP tagged con-
structs (kind gift from Dr Joachim Weis, Aachen) using lipofect-
amine 2000 reagent (ThermoFisher Scientific) according to
manufacturer’s instructions. After 24 h incubation at 37C, cells
were washed twice with pre-warmed PBS and then serum-
starved for 2 h. Growth medium containing 50 ng/ml of nerve
growth factor (NGF) (Sigma–Aldrich) was then applied to stimu-
late internalization of TrkA receptors for 15 min. Serum- and
NGF-free medium was then added to allow recycling of recep-
tors back to the surface. Cells were fixed before NGF application
(pre-NGF) and after NGF application at time points 0, 10, 30, 60
and 180 min in 1:1 4% paraformaldehyde: growth medium at
37C for 5 min. Cells were mounted on slides with ProLong
Diamond Anti-fade Mountant with DAPI (Molecular probes) and
analysed using a Nikon A1R laser scanning confocal micro-
scope. Cells were analysed at 50 per time point and the entire
experiment repeated 4 times, giving a total of 200 cells per time
point. In order to assess protein levels of TrkA throughout the
experiment, cells were also seeded onto 10 cm2 plates and
transfected with the TrkA constructs as above. Following appli-
cation of NGF, cells were lysed at different time points as in the
immunoblotting section and a western blot performed using
the TrkA anti-body (Supplementary Material, Table S1). This
was performed three times. Global endo and exocytosis was
also assessed using FM 1–43, this is described in the
Supplementary Material, Methods.
Time-lapse imaging
NSC-34 control and MYO9A-depleted cells were seeded onto eight
well glass bottom m-slides (Ibidi) and transfected with the coding
sequence of the TrkA receptor as in the recycling assay. After 24 h,
a ROCK inhibitor (InSolutionTM Y-27632—Calbiochem), was ap-
plied at 3nM in serum-free growth medium over-night and
NucRed Live 647 ReadyProbes reagent (Invitrogen) was applied for
visualization of nuclei. Cells were imaged using a Nikon A1R laser
scanning confocal microscope over a period of ten minutes per
cell, with z-stacks obtained. Resulting image series were then ana-
lysed using Imaris, with automatic detection of TrkA positive vesi-
cles based on thresholding that was manually edited. Vesicles
were then tracked by the software over-time and in 3D space to
provide an output for speed the vesicles travelled, 10 cells were
analysed per condition over three experimental repeats.
Secretomic analysis of MYO9A-depleted cells
NSC-34 cells (three samples of both wild-type and MYO9A-
depleted) were cultured to 80% confluency and washed three
times with PBS. Serum-free growth medium was added for 4 h,
followed by the addition of growth medium supplemented with
10% FBS for 1 h (pulse). Following three washes with PBS,
serum-free medium was applied for 3 h (chase) and then col-
lected and centrifuged for 4 min at 1750g. The supernatant was
combined with 10 ice-cold ultrapure ethanol over-night at -
80C. Samples were then centrifuged at 18 000g for 30 min at 4C
and the pellets dried under laminar hood flow before the addi-
tion of SDS lysis buffer (50 mM Tris–HCl pH 7.8, 150 mM NaCl, 1%
SDS, 1 protease cOmplete mini tablet and one phosphatase in-
hibitor PhosSTOP tablet, Roche). Samples were subjected to
quantitative mass spectrometry as outlined in Supplementary
Material, Methods. Criteria for defining a protein as regulated
are: protein commonly quantified in each replicate, identified
by at least one unique peptide, an ANOVA P-value of <0.05 and
an average log 2 ratio of either lower than the down-regulated
cut-off or higher than the up-regulated cut-off (<-4.44 or >4.06).
Zebrafish morpholino injections and NT-1654 treatment
Morpholino-mediated knockdown of zebrafish embryos was
performed with an anti-sense morpholino oligonucleotide (MO)
as previously described for the zebrafish MYO9A orthologues;
myo9aa and myo9ab (6). Briefly, knockdown was performed on
one-cell stage embryos of the AB strain of zebrafish and they
were either uninjected, injected with NT-1654 alone, MO alone
or NT-1654 and MO. The artificial agrin compound, NT-1654, is a
44 kDa fragment of neural agrin that is soluble and resistant to
neurotrypsin cleavage, developed by Neurotune (16). Embryos
from the same pair of fish were split into each of the four cate-
gories to ensure fair comparisons for survival and developmen-
tal rate. At 24 h post-fertilization (hpf), zebrafish from each
condition were recorded for 1 min per dish (>40 zebrafish per
condition) and movements within the chorion recorded per
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fish. This was performed using a Leica stereomicroscope with a
Chameleon digital camera (CMLN-13s2M). At 48 hpf zebrafish
were again recorded following dechorionation and a period of
acclimatization, to quantify their response to tactile stimulation
of the back of the head using a fine pipette tip (average 34 zebra-
fish per condition), as described (19). Videos were obtained us-
ing a Canon legria hfr76 camera at 25 frames per second.
Embryos were placed individually in a petri dish containing E3
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4
and 10 lg/100 ml Methylene Blue) on an illuminated stage.
Room temperature remained constant at 28C throughout the
experiment. The video camera was held using a clamp at 7 cm
above the dish for every experiment and a ruler was used to ad-
just the scale used for measuring in ImageJ for each repeat. Fiji
ImageJ was utilized to quantify the data obtained, with files im-
ported into ImageJ as FFmpeg movies and thresholding applied
to allow visualization of the zebrafish followed by conversion to
a binary image. The Trackmate plugin was then utilized to mea-
sure the movement of the zebrafish, with manual editing of
each reading performed to ensure the zebrafish is tracked cor-
rectly through each video frame. Values for average speed, ac-
celeration and total distance travelled were obtained and
compared between treatment groups.
Immunofluorescent staining of whole mount zebrafish
At 48 hpf, zebrafish embryos from each treatment group were
dechorionated using Pronase E (Sigma–Aldrich) and euthanized
by anaesthetic over-dose. Whole mount staining was performed
as described previously (54), utilizing a mouse anti-SV2 anti-
body to visualize the motor neurons (1:200, Developmental
Studies Hybridoma Bank) and Alexa Fluor 488-a-bungarotoxin
conjugate (1:1000, Life technologies). Z-stack images encom-
passing the entire zebrafish tail were obtained using a 20 air
objective on a Nikon A1R confocal microscope.
Statistics
Statistical analysis was performed using GraphPad Prism soft-
ware and either the Mann–Whitney or unpaired t-test was uti-
lized, following assessment for normal distribution. Statistical
significance was taken as P< 0.05. In vitro experiments were
blinded for image analysis and in vivo experiments blinded prior
to live recording and for image acquisition.
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